Comparison between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents
Not Applicable
Completed
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0007837
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
(1) Subject must be at least 20 years of age.
(2) Patients undergoing percutaneous coronary intervention with drug-eluting stents
(3) Signed written informed consent
Exclusion Criteria
(1) known hypersensibility to aspirin, prasugrel, clopidogrel, ticagrelor, everolimus, sirolimus, contrast medium
(2) Active bleeding
(3) Cardiogenic shock
(4) Pregnant or breast-feeding women or Female of childbearing potential, who possibly plan to become pregnant any time after enrollment into this study
(5) Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may result in protocol non-compliance (per site investigator's medical judgment).
(6) DES implantation within 12 months before index procedure
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A composite of death, myocardial infarction, or cerebrovascular events
- Secondary Outcome Measures
Name Time Method All death, cardiac death, Myocardial infarction (MI), Cerebrovascular accident (CVA), Target lesion revascularization (TLR), Target vessel revascularization (TVR), Any revascularization, Stent thrombosis: definite or probable stent thrombosis by ARC definition, BARC bleeding =2, BARC bleeding =3, Major adverse cardiocerebral event (MACCE): death, MI, CVA, or any revascularization